BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31928169)

  • 21. Mathematical Modeling of Free Thyroxine Concentrations During Methimazole Treatment for Graves' Disease: Development and Validation of a Computer-Aided Thyroid Treatment Method.
    Theiler-Schwetz V; Benninger T; Trummer C; Pilz S; Reichhartinger M
    Front Endocrinol (Lausanne); 2022; 13():841888. PubMed ID: 35721705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
    El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
    J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
    Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A patient-specific treatment model for Graves' hyperthyroidism.
    Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
    Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
    J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioiodine uptake after monotherapy with potassium iodide in patients with Graves' disease.
    Mikura K; Yoshimura Noh J; Watanabe N; Aida A; Yoshimura R; Kinoshita A; Suzuki A; Suzuki N; Fukushita M; Matsumoto M; Yoshihara A; Sugino K; Ito K
    Endocr J; 2023 May; 70(5):541-549. PubMed ID: 36843112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects.
    Okamura K; Sato K; Fujikawa M; Bandai S; Ikenoue H; Kitazono T
    J Clin Endocrinol Metab; 2014 Nov; 99(11):3995-4002. PubMed ID: 25144628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.
    Song A; Kim SJ; Kim MS; Kim J; Kim I; Bae GY; Seo E; Cho YS; Choi JY; Cho SY; Jin DK
    Front Endocrinol (Lausanne); 2021; 12():687834. PubMed ID: 34194397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated serum granulocyte colony-stimulating factor levels in patients with Graves' disease.
    Iitaka M; Noh JY; Kitahama S; Fukasawa N; Miura S; Kawakami Y; Kawasaki S; Yamanaka K; Ishii J; Katayama S; Ito K
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):275-80. PubMed ID: 9578815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience of treating Graves' hyperthyroidism complicated with malignancy-The possible role of potassium iodide for avoiding the risk of thionamide-associated neutropenia.
    Okamura K; Bandai S; Fujikawa M; Sato K; Kitazono T
    Endocr J; 2020 Jul; 67(7):751-758. PubMed ID: 32238669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy.
    Gianetti E; Russo L; Orlandi F; Chiovato L; Giusti M; Benvenga S; Moleti M; Vermiglio F; Macchia PE; Vitale M; Regalbuto C; Centanni M; Martino E; Vitti P; Tonacchera M
    J Endocrinol Invest; 2015 Sep; 38(9):977-85. PubMed ID: 25840794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of hyperthyroidism due to Graves' disease: what is the recommended antithyroid drug during pregnancy?].
    Caron P
    J Gynecol Obstet Biol Reprod (Paris); 2013 May; 42(3):232-7. PubMed ID: 23312275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease.
    Kim HJ; Bang JI; Kim JY; Moon JH; So Y; Lee WW
    Korean J Radiol; 2017; 18(3):543-550. PubMed ID: 28458607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
    Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
    Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remission of insulin autoimmune syndrome in a patient with Grave's disease by treatment with methimazole.
    Okabe R; Inaba M; Hosoi M; Ishimura E; Kumeda Y; Nishizawa Y; Morii H
    Intern Med; 1999 Jun; 38(6):482-5. PubMed ID: 10411353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.